Recent evidence shows that the lack or the inhibition of P2X7 alters eATP levels and modulates CD39, CD73, and adenosine receptor A2A in both immune-infiltrating and cancer cells [7, 14, 15] strongly suggesting that the manipulation of P2X7 receptor activity affects the entire purinergic/adenosinergic axis in the TME. The gene discussed is ENTPD1; the disease is cancer.